HX8

Drug Profile

HX8

Alternative Names: Anti-HSV antibody-HX8

Latest Information Update: 18 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ReProtect LLC
  • Developer Biolex; Dow Chemical; ReProtect LLC
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 18 May 2007 Discontinued - Preclinical for Herpes simplex virus infections in USA (Vaginal)
  • 06 May 2004 Epicyte Pharmaceutical has been acquired and merged into Biolex
  • 11 Sep 2002 A Plantibodies™ candidate anti-HSV antibody (HX8) has been identified
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top